UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2024

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒  Form 40-F ☐

 

 

 

In February 2024, Sanofi published the press releases attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5 which are incorporated herein by reference.

Exhibit Index

 

Exhibit No.		Description
Exhibit 99.1		Press Release dated February 15, 2024: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
Exhibit 99.2		Press Release dated February 16, 2024: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Exhibit 99.3		Press Release dated February  22, 2024: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Exhibit 99.4		Press Release dated February 23, 2024: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Exhibit 99.5		Press Release dated February  24, 2024: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: February 27, 2024						SANOFI
				By		/s/ Alexandra Roger
						Name: Alexandra Roger
						Title: Head of Legal Corporate & Finance

 

3